Treatment of rna virus infection with a cytidine
AssigneeThe Cleveland Clinic Foundation
InventorsYogen Saunthararajah, Babal K. Jha, Xiaorong Gu
Life of this patent
Estimating the term…
Abstract
The present invention provides compositions, systems, kits, and methods for treating a subject with an RNA virus infection (e.g., SARS-COV-2) by administering or providing a composition comprising a cytidine deaminase inhibitor (e.g., tetrahy-drouridine or cedazuridine).
Claims33
A method of treating a subject infected with an RNA virus comprising:
- administering a composition to a subject, or providing said composition to said subject such that said subject administers said composition to themselves;
- wherein said subject is infected with an RNA virus;
- wherein said composition comprises a cytidine deaminase inhibitor.
ethod of claim 1, wherein said cytidine deaminase inhibitor comprises a compound of Formula I, wherein Formula I is as follows:
- or a pharmaceutically acceptable salt of the compound, wherein:
- R1 and R2 are independently selected from the group consisting of hydrogen, halo, cyano, nitro, sulfhydryl, hydroxyl, formyl, carboxyl, COO (C1 to C6 straight or branched chain alkyl), COO (C1 to C6 straight or branched chain alkenyl), COO (C1 to C6 straight or branched chain alkynyl), CO (C1 to C6 straight or branched chain alkyl), CO (C1 to C6 straight or branched chain alkenyl), CO (C1 to C6 straight or branched chain alkynyl), C1 to C6 straight or branched chain alkyl, C1 to C6 straight or branched chain alkenyl, C1 to C6 straight or branched chain alkynyl, C1 to C6 straight or branched chain alkoxy, and C1 to C6 straight or branched chain alkenoxy;
- wherein each occurrence of C1 to C6 straight or branched chain alkyl, C1 to C6 straight or branched chain alkenyl, C1 to C6 straight or branched chain alkynyl, C1 to C6 straight or branched chain alkoxy, or C1 to C6 straight or branched chain alkenoxy, may be independently unsubstituted or substituted with one to four substituents independently selected from the group consisting of halo, hydroxyl, cyano, nitro, formyl, carboxyl, and sulfhydryl;
- and provided that when one of R1 and R2 is —H, then the other is not —H, —OH or —CH2OH.
A system, kit, or article of manufacture comprising:
- a) a composition comprising a cytidine deaminase inhibitor;
- and
- b) a container selected from the group consisting of:
- i) an airway administration device, and
- ii) an orally ingestible dosage form.
A composition comprising:
- a) a cytidine deaminase inhibitor;
- and
- b) an RNA virus.
An in vitro composition comprising:
- a) a cytidine deaminase inhibitor;
- and
- b) an inhibitor of pyrimidine synthesis.
A system or kit comprising:
- a) a composition a cytidine deaminase inhibitor;
- and
- b) instructions for treating a subject with said composition, wherein said subject is infected with:
- an RNA virus.
An article of manufacture comprising an orally ingestible pill or capsule, wherein said orally ingestible pill or capsule comprises:
- a) a composition comprising a cytidine deaminase inhibitor;
- and
- b) an enteric coating which surrounds said composition.
Dependencies are inferred from the claim text.